Biologics are very specific, highly effective medicines made in living cells, and historically this was often an animal. Biologics include hormones, cytokines, growth factors, vaccines, gene and cellular therapies, fusion proteins, insulin, interferon, and monoclonal antibody (mAb) products.
A biosimilar (also known as follow-on biologic or subsequent entry biologic) is a biologic medical product that is almost an identical copy of an original product that manufactured by a different company. Biosimilar are officially approved versions of original "innovator" products and can manufactured when the original product's patent expires. Reference to the innovator product is an integral component of the approval.
The global Innovations in Biologics and Biosimilars market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Innovations in Biologics and Biosimilars is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Innovations in Biologics and Biosimilars is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Innovations in Biologics and Biosimilars in Hospital is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Innovations in Biologics and Biosimilars include Roche, Amgen, AbbVie, Sanofi, Johnson & Johnson, Pfizer, Novo Nordisk, Eli Lilly, Novartis, Merck, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Innovations in Biologics and Biosimilars, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Innovations in Biologics and Biosimilars.
The Innovations in Biologics and Biosimilars market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Innovations in Biologics and Biosimilars market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Innovations in Biologics and Biosimilars companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Roche
Amgen
AbbVie
Sanofi
Johnson & Johnson
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Merck
Biogen
Celltrion
Sobi
3SBIO
Changchun High Tech
Kanghong Pharma
Innovent Biologics
Gan&Lee
Tonghua Dongbao
United Laboratory
Segment by Type
Monoclonal Antibodies
Interferon
Insulin
Vaccines
Others
Segment by Application
Hospital
Retail Pharmacy
Other
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Innovations in Biologics and Biosimilars company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Innovations in Biologics and Biosimilars 麻豆原创 Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Monoclonal Antibodies
1.2.3 Interferon
1.2.4 Insulin
1.2.5 Vaccines
1.2.6 Others
1.3 麻豆原创 by Application
1.3.1 Global Innovations in Biologics and Biosimilars 麻豆原创 Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Innovations in Biologics and Biosimilars 麻豆原创 Perspective (2019-2030)
2.2 Global Innovations in Biologics and Biosimilars Growth Trends by Region
2.2.1 Global Innovations in Biologics and Biosimilars 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Innovations in Biologics and Biosimilars Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Innovations in Biologics and Biosimilars Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Innovations in Biologics and Biosimilars 麻豆原创 Dynamics
2.3.1 Innovations in Biologics and Biosimilars Industry Trends
2.3.2 Innovations in Biologics and Biosimilars 麻豆原创 Drivers
2.3.3 Innovations in Biologics and Biosimilars 麻豆原创 Challenges
2.3.4 Innovations in Biologics and Biosimilars 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Innovations in Biologics and Biosimilars Players by Revenue
3.1.1 Global Top Innovations in Biologics and Biosimilars Players by Revenue (2019-2024)
3.1.2 Global Innovations in Biologics and Biosimilars Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Innovations in Biologics and Biosimilars 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Innovations in Biologics and Biosimilars Revenue
3.4 Global Innovations in Biologics and Biosimilars 麻豆原创 Concentration Ratio
3.4.1 Global Innovations in Biologics and Biosimilars 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Innovations in Biologics and Biosimilars Revenue in 2023
3.5 Global Key Players of Innovations in Biologics and Biosimilars Head office and Area Served
3.6 Global Key Players of Innovations in Biologics and Biosimilars, Product and Application
3.7 Global Key Players of Innovations in Biologics and Biosimilars, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Innovations in Biologics and Biosimilars Breakdown Data by Type
4.1 Global Innovations in Biologics and Biosimilars Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Innovations in Biologics and Biosimilars Forecasted 麻豆原创 Size by Type (2025-2030)
5 Innovations in Biologics and Biosimilars Breakdown Data by Application
5.1 Global Innovations in Biologics and Biosimilars Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Innovations in Biologics and Biosimilars Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Innovations in Biologics and Biosimilars 麻豆原创 Size (2019-2030)
6.2 North America Innovations in Biologics and Biosimilars 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Innovations in Biologics and Biosimilars 麻豆原创 Size by Country (2019-2024)
6.4 North America Innovations in Biologics and Biosimilars 麻豆原创 Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Innovations in Biologics and Biosimilars 麻豆原创 Size (2019-2030)
7.2 Europe Innovations in Biologics and Biosimilars 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Innovations in Biologics and Biosimilars 麻豆原创 Size by Country (2019-2024)
7.4 Europe Innovations in Biologics and Biosimilars 麻豆原创 Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Innovations in Biologics and Biosimilars 麻豆原创 Size (2019-2030)
8.2 Asia-Pacific Innovations in Biologics and Biosimilars 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Innovations in Biologics and Biosimilars 麻豆原创 Size by Region (2019-2024)
8.4 Asia-Pacific Innovations in Biologics and Biosimilars 麻豆原创 Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Innovations in Biologics and Biosimilars 麻豆原创 Size (2019-2030)
9.2 Latin America Innovations in Biologics and Biosimilars 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Innovations in Biologics and Biosimilars 麻豆原创 Size by Country (2019-2024)
9.4 Latin America Innovations in Biologics and Biosimilars 麻豆原创 Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Innovations in Biologics and Biosimilars 麻豆原创 Size (2019-2030)
10.2 Middle East & Africa Innovations in Biologics and Biosimilars 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Innovations in Biologics and Biosimilars 麻豆原创 Size by Country (2019-2024)
10.4 Middle East & Africa Innovations in Biologics and Biosimilars 麻豆原创 Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Details
11.1.2 Roche Business Overview
11.1.3 Roche Innovations in Biologics and Biosimilars Introduction
11.1.4 Roche Revenue in Innovations in Biologics and Biosimilars Business (2019-2024)
11.1.5 Roche Recent Development
11.2 Amgen
11.2.1 Amgen Company Details
11.2.2 Amgen Business Overview
11.2.3 Amgen Innovations in Biologics and Biosimilars Introduction
11.2.4 Amgen Revenue in Innovations in Biologics and Biosimilars Business (2019-2024)
11.2.5 Amgen Recent Development
11.3 AbbVie
11.3.1 AbbVie Company Details
11.3.2 AbbVie Business Overview
11.3.3 AbbVie Innovations in Biologics and Biosimilars Introduction
11.3.4 AbbVie Revenue in Innovations in Biologics and Biosimilars Business (2019-2024)
11.3.5 AbbVie Recent Development
11.4 Sanofi
11.4.1 Sanofi Company Details
11.4.2 Sanofi Business Overview
11.4.3 Sanofi Innovations in Biologics and Biosimilars Introduction
11.4.4 Sanofi Revenue in Innovations in Biologics and Biosimilars Business (2019-2024)
11.4.5 Sanofi Recent Development
11.5 Johnson & Johnson
11.5.1 Johnson & Johnson Company Details
11.5.2 Johnson & Johnson Business Overview
11.5.3 Johnson & Johnson Innovations in Biologics and Biosimilars Introduction
11.5.4 Johnson & Johnson Revenue in Innovations in Biologics and Biosimilars Business (2019-2024)
11.5.5 Johnson & Johnson Recent Development
11.6 Pfizer
11.6.1 Pfizer Company Details
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Innovations in Biologics and Biosimilars Introduction
11.6.4 Pfizer Revenue in Innovations in Biologics and Biosimilars Business (2019-2024)
11.6.5 Pfizer Recent Development
11.7 Novo Nordisk
11.7.1 Novo Nordisk Company Details
11.7.2 Novo Nordisk Business Overview
11.7.3 Novo Nordisk Innovations in Biologics and Biosimilars Introduction
11.7.4 Novo Nordisk Revenue in Innovations in Biologics and Biosimilars Business (2019-2024)
11.7.5 Novo Nordisk Recent Development
11.8 Eli Lilly
11.8.1 Eli Lilly Company Details
11.8.2 Eli Lilly Business Overview
11.8.3 Eli Lilly Innovations in Biologics and Biosimilars Introduction
11.8.4 Eli Lilly Revenue in Innovations in Biologics and Biosimilars Business (2019-2024)
11.8.5 Eli Lilly Recent Development
11.9 Novartis
11.9.1 Novartis Company Details
11.9.2 Novartis Business Overview
11.9.3 Novartis Innovations in Biologics and Biosimilars Introduction
11.9.4 Novartis Revenue in Innovations in Biologics and Biosimilars Business (2019-2024)
11.9.5 Novartis Recent Development
11.10 Merck
11.10.1 Merck Company Details
11.10.2 Merck Business Overview
11.10.3 Merck Innovations in Biologics and Biosimilars Introduction
11.10.4 Merck Revenue in Innovations in Biologics and Biosimilars Business (2019-2024)
11.10.5 Merck Recent Development
11.11 Biogen
11.11.1 Biogen Company Details
11.11.2 Biogen Business Overview
11.11.3 Biogen Innovations in Biologics and Biosimilars Introduction
11.11.4 Biogen Revenue in Innovations in Biologics and Biosimilars Business (2019-2024)
11.11.5 Biogen Recent Development
11.12 Celltrion
11.12.1 Celltrion Company Details
11.12.2 Celltrion Business Overview
11.12.3 Celltrion Innovations in Biologics and Biosimilars Introduction
11.12.4 Celltrion Revenue in Innovations in Biologics and Biosimilars Business (2019-2024)
11.12.5 Celltrion Recent Development
11.13 Sobi
11.13.1 Sobi Company Details
11.13.2 Sobi Business Overview
11.13.3 Sobi Innovations in Biologics and Biosimilars Introduction
11.13.4 Sobi Revenue in Innovations in Biologics and Biosimilars Business (2019-2024)
11.13.5 Sobi Recent Development
11.14 3SBIO
11.14.1 3SBIO Company Details
11.14.2 3SBIO Business Overview
11.14.3 3SBIO Innovations in Biologics and Biosimilars Introduction
11.14.4 3SBIO Revenue in Innovations in Biologics and Biosimilars Business (2019-2024)
11.14.5 3SBIO Recent Development
11.15 Changchun High Tech
11.15.1 Changchun High Tech Company Details
11.15.2 Changchun High Tech Business Overview
11.15.3 Changchun High Tech Innovations in Biologics and Biosimilars Introduction
11.15.4 Changchun High Tech Revenue in Innovations in Biologics and Biosimilars Business (2019-2024)
11.15.5 Changchun High Tech Recent Development
11.16 Kanghong Pharma
11.16.1 Kanghong Pharma Company Details
11.16.2 Kanghong Pharma Business Overview
11.16.3 Kanghong Pharma Innovations in Biologics and Biosimilars Introduction
11.16.4 Kanghong Pharma Revenue in Innovations in Biologics and Biosimilars Business (2019-2024)
11.16.5 Kanghong Pharma Recent Development
11.17 Innovent Biologics
11.17.1 Innovent Biologics Company Details
11.17.2 Innovent Biologics Business Overview
11.17.3 Innovent Biologics Innovations in Biologics and Biosimilars Introduction
11.17.4 Innovent Biologics Revenue in Innovations in Biologics and Biosimilars Business (2019-2024)
11.17.5 Innovent Biologics Recent Development
11.18 Gan&Lee
11.18.1 Gan&Lee Company Details
11.18.2 Gan&Lee Business Overview
11.18.3 Gan&Lee Innovations in Biologics and Biosimilars Introduction
11.18.4 Gan&Lee Revenue in Innovations in Biologics and Biosimilars Business (2019-2024)
11.18.5 Gan&Lee Recent Development
11.19 Tonghua Dongbao
11.19.1 Tonghua Dongbao Company Details
11.19.2 Tonghua Dongbao Business Overview
11.19.3 Tonghua Dongbao Innovations in Biologics and Biosimilars Introduction
11.19.4 Tonghua Dongbao Revenue in Innovations in Biologics and Biosimilars Business (2019-2024)
11.19.5 Tonghua Dongbao Recent Development
11.20 United Laboratory
11.20.1 United Laboratory Company Details
11.20.2 United Laboratory Business Overview
11.20.3 United Laboratory Innovations in Biologics and Biosimilars Introduction
11.20.4 United Laboratory Revenue in Innovations in Biologics and Biosimilars Business (2019-2024)
11.20.5 United Laboratory Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 麻豆原创 Size Estimation
13.1.1.3 麻豆原创 Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
Roche
Amgen
AbbVie
Sanofi
Johnson & Johnson
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Merck
Biogen
Celltrion
Sobi
3SBIO
Changchun High Tech
Kanghong Pharma
Innovent Biologics
Gan&Lee
Tonghua Dongbao
United Laboratory
听
听
*If Applicable.